• About us
• Contact

Advertisement

Organisation › Details

Epidarex Capital (Group)

Epidarex Capital is a transatlantic venture fund that invests in early-stage, high growth life science and health technology companies in under-ventured markets. Epidarex focuses on providing risk capital to young companies, including spin-outs, from leading research institutions in both established and emerging life science hubs. The fund’s international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market. *

 

	Start	2016-03-22 existent
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Roper, Elizabeth (Liz) (Epidarex Capital 2013– Partner before Chroma Therapeutics + Wellcome Trust VC team)
	Street	7910 Woodmont Avenue Suite 210
	City	20814 Bethesda, MD
	Tel	+1-301-298-5455
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Epidarex Capital. (12/9/19). "Press Release: Epidarex Exeed Founded by Epidarex Capital to Advance Early Stage, Highly Innovative Life Science Assets". Edinburgh.
		Record changed: 2022-06-02

Advertisement

More documents for Epidarex Capital (Group)

• [1] Transine Therapeutics Ltd.. (5/31/22). "Press Release: Transine Therapeutics Announces Final Closing of Its Seed Round at £13.7m to Accelerate Its Platform and Portfolio Development". Cambridge....
• [2] Kynos Therapeutics Ltd.. (4/7/22). "Press Release: Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor". Edinburgh....
• [3] Dunad Therapeutics. (3/23/21). "Press Release: Dunad Therapeutics Emerges to Develop Next-generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology". Cambridge....
• [4] Slate Bio, Inc.. (1/19/21). "Press Release: Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies". Charlottesville, VA....
• [5] Theolytics Ltd.. (1/7/21). "Press Release: Theolytics Raises $6.8 Million Series A Round Co-led by Epidarex Capital and Taiho Ventures to Advance Viral Cancer Therapies". Oxford....
• [6] Epidarex Capital. (6/22/20). "Press Release: Epidarex Capital Closes New £102 Million UK Venture Fund to Build Successful Life Science Companies". Edinburgh....
• [7] Epidarex Capital. (12/9/19). "Press Release: Epidarex Exeed Founded by Epidarex Capital to Advance Early Stage, Highly Innovative Life Science Assets". Edinburgh....
• [8] Lunac Therapeutics Ltd.. (11/14/19). "Press Release: Lunac Therapeutics Spun Out to Develop Next Generation Anticoagulants, and Announces Series A Funding Round". Leeds....
• [9] AdoRx Therapeutics Ltd.. (6/21/18). "Press Release: AdoRx Therapeutics Announces Initial funding of $10 Million for the Discovery of New Cancer Therapeutics". Edinburgh....
• [10] Eternygen GmbH. (1/9/17). "Press Release: Eternygen GmbH Closes € 8.0 (US$ 8.3) Million Series A Financing led by Epidarex Capital". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.